Introduction
The basic achievements of the past 30 years which have led to a better understanding of the biochemistry of lipids in health and disease have arisen from the characterisation of the lipoprotein system by both the structural properties and metabolism of the plasma lipoproteins. It is now apparent that the regulatory mechanisms for maintaining normal plasma lipid concentrations are dependent on a normal metabolism not only of the lipids but also of the carbohydrates and proteins.
Any approach to elucidate the physiological, pathobiochemical or clinical significance of the different lipoproteins necessitates a consideration of the multifactorial control mechanisms regulating the lipoprotein system. A considerable body of data has been accumulated in the past, indicating that lipoprotein changes, both qualitative and quantitative, are induced by physiological and pathological processes. These may be divided into three major groups:
(a) genetically directed dyslipoproteinaemias; (b) lipoprotein changes caused by environmental factors; and (c) lipoprotein changes in disease.
The primary forms of hyperlipoproteinaemia are closely linked to the early development of atherosclerotic vascular disease. Secondary dyslipoproteinaemias are frequent and profound in liver disease, pancreatic, intestinal, and kidney disease, hormonal dysfunction, diabetes, various forms of autoimmune and neoplastic disease, dysproteinaemia including hypoor a-apoproteinaemia and in lecithin .cholesterol acyl transferase deficiency.
In the last decade methods have been developed for quantitation of the different lipoprotein-fractions and of their corresponding lipids and apoproteins. The requirements and possibilities of the various methods available today for routine use need relevant and critical evaluation. An up-to-date synopsis of Fig. t Table 2 Functions of the human apolipoproteins each of these physically defined groups, and therefore a nomenclature based on the apoprotein composition of the lipoproteins was suggested," Until now nine different major apoproteins have been identified; some of them are carefully characterised (Tables 1  and 2) .
Quantitatively, apoproteins A I and A II are the predominant proteins of normal HDL. Apoprotein B is considered to be the major protein of the LDL density class or the~-lipoproteins. Apo C is the predominant protein of mature VLDL. The minor apoprotein components of the lipoproteins, Apo D, E, and F, are distributed throughout the spectrum. Plasma triglycerides are accumulated in VLDL cholesterol in LDL, and phospholipids primarily in HDL.
The heterogeneity of any physicochemically defined lipoprotein fraction is further complicated by movements of both lipids and the apoproteins between the different particles during their metabolism in the vascular space. Some of the mechanisms regulating this dynamic and complex metabolic system have been elucidated during the last ten years. s They enable us today to draw a much more detailed picture of lipid metabolism in general and also of its impact upon the pathophysiology of various diseased states ( Fig. 3) .
Apart from the intestine, the liver plays the major Heterogeneity, however, is also recognised within role in biosynthesis of plasma lipoproteins and subserves a central role in lipoprotein metabolism. The liver secretes two types of nascent lipoproteins, one is a nascent VLDL, rich in triglycerides and apo B with very little apo C and apo E. The other is a nascent HDL rich in phospholipids, unesterified cholesterol apo E, A II, and some apo C. These particles have a laminar structure. After its entry into the plasma, nascent HDLs are acted upon by lecithin :cholesterol acyltransferase (LCAT), an enzyme also secreted by the liver. Cholesterol is esterified, becoming hydrophobic, and is therefore transferred into the core of the particle. This causes a change in the shape of the particles; they become globular. This runs parallel with an exchange of apo E and apo C versus A I. The latter is the cofactor of the LCAT enzyme and derives predominantly from the intestine. As esterification takes place apo C and apparently also apo E are transferred to the nascent VLDL. Mediated by apo D, cholesterol ester is transferred from HDL to the pathway leading from nascent VLDL to mature VLDL, intermediate density lipoprotein particles, and finally to LDL. This metabolic cascade is regulated by lipoprotein lipase and possibly by hepatic triglyceride hydrolase, the two major enzymes of postheparin lipolytic activity. During triglyceride hydrolysis some apo C and apo E is transferred back to the HDL density fraction. The A I rich, mature HDLs are believed to be catabolised primarily by the liver. The liver under normal conditions also removes chylomicron rem-nants through apo E surface receptors and metabolises cholesterol, triglycerides, and phospholipids. It also excretes lipids, possibly as lipid-protein complexes, with the bile fluid. Disturbances of liver function are therefore often accompanied by abnormal plasma lipid and lipoprotein concentrations, a phenomenon recorded more than a century ago by Flint. 4 Since then a variety of interesting abnormalities of the lipoprotein system have been described," some of which are disease-specific, while others are helpful for monitoring the course of hepatic disease.
Any attempt to elucidate the physiological, pathobiochemical, or clinical significance of the different lipoproteins demands consideration of the multifactorial control mechanisms and factors regulating the lipoprotein system. These are in principle:
intestinal absorption, synthetic rates of lipids and apoproteins, assembly and secretion of lipoproteins, structure of apoproteins, structure of lipoproteins, enzymes involved in the interconversion and intravascular metabolism of the lipoproteins (lipases and LCAT), recognition, uptake, and degradation of lipoproteins by cells, transformation and elimination of lipids and sterols by the liver.
Lipoprotein changes
A considerable quantity of data has accumulated in the past decades, indicating that both qualitative and quantitative lipoprotein changes are induced by physiological and pathological processes.s These may be divided into three major groups:
(A) genetically directed dyslipoproteinaemias, (B) lipoprotein changes caused by environmental factors, (C) lipoprotein changes in disease.
GROUP A
Genetically directed dyslipoproteinaemias are numerous and include: familial forms of hyperlipoproteinaemia (originally described as Frederickson types I-Vas well as combined forms); primary, non-familial forms of hyperlipoproteinaemia (types II and IV and combined forms); familial hyper-alpha-lipoproteinaemia; Tangier disease (deficiency of apo A); deficiency of apoproteins C II and E; hypo-and a-js-lipoproteinaemia ; familial lecithin :cholesterol acyltransferase deficiency; glycogen-storage and different forms of lipidstorage disease.
GROUP B
We now have clear evidence from clinical, epidemiological, and experimental studies that environmental factors strongly influence the lipoprotein system. Well established factors are: nutritional habits, alcohol intake, body weight, smoking habits, physical activities, and a number of chemotherapeutic managements.
GROUP C
Lipoprotein changes induced by diseased processes are found in arterial vascular disease, renal disease, diabetes, gout, hormonal dysregulation, pancreatic dysfunction, intestinal disease, autoimmune and neoplastic disease, and especially in liver disease.
The association between elevated concentrations of plasma cholesterol and also elevation of [3- lipoprotein cholesterol with increased cardiovascular risk was indeed the major stimulus for focusing attention on the circulating lipoproteins. However the application of our present basic knowledge about the metabolic and structural properties of the different lipoprotein particles in clinical medicine evokes both questions and criticisms, because it often failed to provide reliable predictions in individuals. One important reason for this has possibly been that measurement of plasma lipids alone, or a semiquantitative estimation of the major lipoprotein fractions performed over many years (for technical reasons), seems inadequate in profiling the lipoprotein spectrum of one subject.
Our laboratory has obtained some preliminary data on the relationship of plasma lipoproteins to coronary artery disease, a subject always of general interest and of great clinical importance.
We correlated the concentration of the different plasma-lipoproteins and apoproteins in individual subjects with the status of their coronary tree, as determined by coronary angiography (n = close to 1000). The quantification of the plasma lipoproteins was achieved by quantitative lipoprotein electrophoresis based on densitometric scanning of the lipoprotein bands after they had been separated by agarose gel electrophoresis and visualised by polyanion precipitation. This method has been shown to be specific and precise for measuring the three major fractions: Ot-lipoproteins, I'-lipoproteins, and pre-js-lipoproteins. This determination correlates extremely well with both ultracentrifugation and quantitative measurement of the major apoproteins, primarily A I and apo B.8 The method allows not only exact quantification of the different fractions but also the estimation of the biologically important 1': ec-lipcprotein ratio with high precision (CV < 3 %).
The patients are classified into two groups on the basis of their coronary angiogram, which was performed in the Department of Cardiology, University Hospital, Gottingen, Group 1 patients had no signs of arterial disease. Group 2 patients were suffering from severe coronary artery disease, that is, more than 50 % occlusion of at least one coronary artery.
Patients with less than 50 % occlusion but with signs of atherosclerotic disease are at present excluded from the statistical evaluation, as are survivors of myocardial infarction, if the event had taken place less than two months before examination. Healthy men 40 to 60 years all were used as controls.
From comparison of the data it became obvious that total cholesterol was higher in the affected than in the unaffected group. Triglycerides were increased but not significantly so. I'-cholesterol was increased by 22 % and highly significant in the affected subjects Pre-js-and ee-lipoprotein concentrations were also increased but with no significant difference between the two groups. The [3:Ot-lipoprotein ratio is increased by 28 % in the affected group and is very significantly different from that in the unaffected group.
Since mean values were not very helpful for clinical assessment in individuals, we attempted to determine criteria from the data for a lipoprotein profile which would be indicative of coronary artery disease in individual subjects. Cut-off points for individual parameters are best estimated from an interpretation of the cumulative frequency curves. It becomes apparent" that total cholesterol separates best by close to 40 %at a level of 230 mg/dl, However, 50 %ofthe affected patients show concentrations below this level. For~-lipoprotein cholesterol the best cut-off point was established at a level of 140 rng/dl, In this case, however, 50% of the unaffected subjects show values above this point. ex-lipoprotein cholesterol does not separate satisfactorily between the two groups, nor does A I or the so-called HDL-cholesterol. Introduction of the~:ex-lipoprotein ratio as an additional parameter shifts the range of differentiation favourably and increases the magnitude of -lipoprotein concentration by about 10%. From the statistical evaluation of the data we derived the following information pertaining to the clinical significance of the lipoprotein profile in individuals."
No risk can be anticipated with a total cholesterol value below 180mg/dl or a~:ex-lipoprotein ratio of <1.
A high risk must be considered if the total cholesterol concentration exceeds 280 mgjdl or if thẽ -cholesterol concentration exceeds 190 mgjdl or if the~: ex-lipoprotein ratio exceeds a value of 2·5.
Cholesterol concentrations between 180 and 280 rng/dl need further interpretation in terms of individual lipoprotein concentration.
An increased risk of coronary artery disease is likely if two of the three following critical values are exceeded: total cholesterol 230 mgjdl;~-lipoprotein cholesterol 140 mgjdl; or~:ex-lipoproteinratio 1· 6.
On the basis of these criteria 80 % of affected patients were detected and only 20% escaped detection. Of the unaffected subjects 70% are correctly classified. The statistical evaluation using the Pearson coefficient of contingence emphasises the diagnostic power of these criteria for a large population and also in individuals. The data support the idea that ã -lipoprotein cholesterol concentration exceeding a critical value (190 mgjdl) must be considered dangerous, whilst the protective effect of ex-lipoprotein seems to be relevant only within a certain range of~-lipoproteincholesterol concentrations (140--190 mg/dl), Comparison of apoprotein measurements (A I and apo B) with quantitative lipoprotein electrophoresis revealed a similar diagnostic power as long as triglyceride concentrations did not exceed 250 mgjdl. I therefore conclude that with the technical possibilities available today in routine laboratories-quantitative lipoprotein electrophoresis is the most powerful practical tool for assessing the plasma lipoprotein spectrum.
Attempts to separate the plasma lipoprotein sys-Seidel tem into two fractions by polyanion precipitation techniques (so-called HDL-cholesterol) does not seem to live up to expectation The reasons are many. The method used is generally not precise enough to measure with accuracy differences of 3-5 mgjdl cholesterol as is required for HDL cholesterol. Measurement of HDL cholesterol does not seem to have the diagnostic power that was predicted. The various methods in use may not measure the same lipoprotein particles.
The results of this clinical study on patients using coronary angiography again underline the importance of hypercholesterolaemia and more specifically hyper-B-lipoprotelnaemia as one of the major risk factors associated with the development of early coronary artery disease, which causes nearly 50 % of deaths in industrialised countries.
Special attention should be given to the concentration of the~-lipoproteins or to the LDL density class as the major fraction transporting cholesterol to the peripheral tissues. Therefore, mechanisms regulating LDL removal are of prime importance in atherogenesis.
The catabolism of low density lipoproteins may follow two different pathways: Pathway 1, the main pathway, accounts for approximately 80 % of LDL removal from the vascular space and is regulated through a high affinity receptor .system located on the cell surface of most tissues.P The~-lipoproteins are bound to this receptor via the protein moiety (apo B) and taken up into the cells in the form of endocytotic vesicles. The apoprotein moiety together with the receptor is hydrolised by lysosomal enzymes to amino acids. The cholesterol esters that are now released from the lipoproteins are cleaved by an acid lysosomal cholesterol esterase, an enzyme that may play a dominant role in atherogenesis. The newly formed free cholesterol can now reach the endoplasmic reticulum where it inhibits hydroxymethylglutaryl (HMG)-CoA-reductase activity and thus depresses cellular cholesterol synthesis. Activity of high affinity receptors is itself regulated via a feedback mechanism. In depletion of cellular cholesterol, there is an increase in apo-B-receptor formation at the cell surface, while accumulation of cholesterol in the cell leads to a diminution of receptors. Through this mechanism most tissues are capable of protecting themselves from uncontrolled cholesterol uptake and accumulation.
In contrast to pathway 1, pathway 2 accounts under normal conditions for about 20 % of LDL removal. The cellular uptake following this pathway is phagocytotic, not receptor-regulated, and therefore unselective, and dependent on the concentration of LDL. Tissues practising this metabolic pathway are unable to protect themselves from an overload of LDL cholesterol, if LDL concentration exceeds a certain critical concentration. This is usually the case if the receptor-regulated pathway is disturbed or exhausted. Uptake of~-lipoproteins usually results in a positive cholesterol balance for cellular cholesterol demands. Cholesterol not utilised by the cells may, to a certain extent, be taken up by HDLs and transferred to the liver for excretion. If the cellular cholesterol balance is not guaranteed, cholesterol may be stored. This takes place primarily in cells capable of phagocytosis, among which are smooth muscle cells and macrophages of the vessel wall. These cells may then change to become foam cells, the characteristic cells of the atherosclerotic plaque.
In summary, I should like to emphasise that our understanding of the structural properties of the plasma lipoproteins and the mechanisms regulating their metabolism have notably increased in recent years. The importance of concentrating on plasma lipoproteins not only in basic research but also in clinical medicine is apparent. It seems obvious that as long as clinical chemical methodology keeps pace with progress in basic research, early recognition of the risk of coronary heart disease and a better understanding of the pathobiochemistry of a wide spectrum of diseases may be expected.
